A comparison of preference assessment instruments used in a clinical trial: responses to the visual analog scale from the EuroQol EQ-5D and the Health Utilities Index.
OBJECTIVE
To compare preference assessments that were made by using the EuroQol EQ-5D and the Health Utilities Index Mark II.


METHODS
561 patients in a randomized trial of tirilazad mesylate for aneurysmal subarachnoid hemorrhage.


METHODS
Three preference assessments (a value score for the EuroQol instrument and value and utility scores for the Health Utilities Index) made three months after randomization. The averages for each of the three scores, stratified by clinical outcomes and attributes of the Health Utilities Index health status classification system, were compared. To evaluate potential sources of difference between the instruments, the authors estimated two alternative Health Utilities Index scoring rules that were based on patient responses to the EuroQol instrument.


RESULTS
Patients' ratings of their current health made by using the 100-point visual analog scale from the EuroQol instrument were more similar to the utility scores for the Health Utilities Index than they were to the value scores for the Health Utilities Index. The biggest differences between the visual analog scores for the EuroQol instrument and the utility scores for the Health Utilities index were seen at higher levels of functioning.


CONCLUSIONS
For states representing higher levels of functioning, differences were seen between patients' self-ratings obtained by using the EuroQol instrument and the patients' utility scores on the Health Utilities Index; for states representing lower levels of functioning, substantial agreement was observed between these two scores. Differences observed at the higher levels of functioning suggest that further research is needed to determine whether the Health Utility Index's assignment of a score of 1.0 to the reference state representing being healthy is appropriate.
Glick
H A
HA
Division of General Internal Medicine and the Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, USA. hlthsvrs@mail.med.upenn.edu
Polsky
D
D
Willke
R J
RJ
Schulman
K A
KA
D000203:Activities of Daily Living / Q000145:classification; D000328:Adult; D000368:Aged; D002170:Canada; D003661:Decision Support Techniques; D004305:Dose-Response Relationship, Drug; D005260:Female; D015600:Glasgow Coma Scale; D006801:Humans; D002532:Intracranial Aneurysm / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010147:Pain Measurement / Q000706:statistics & numerical data*; D017060:Patient Satisfaction; D011281:Pregnatrienes / Q000008:administration & dosage* / Q000009:adverse effects; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy*; D016896:Treatment Outcome; D014481:United States
D018696:Neuroprotective Agents; D011281:Pregnatrienes; C053355:tirilazad